tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

XFOR Stock Latest News

X4 Pharmaceuticals selloff brings opportunity, says H.C. Wainwright
The FlyX4 Pharmaceuticals selloff brings opportunity, says H.C. Wainwright
5d ago
XFOR
X4 Pharmaceuticals Advances CN Treatment with Mavorixafor Trials
PremiumCompany Announcements
X4 Pharmaceuticals Advances CN Treatment with Mavorixafor Trials
6d ago
8K
XFOR
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
PremiumPress Releases
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
6d ago
XFOR
X4 Pharmaceuticals’ mavorixafor shows efficacy in chronic neutropenia
PremiumThe Fly
X4 Pharmaceuticals’ mavorixafor shows efficacy in chronic neutropenia
6d ago
XFOR
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30d ago
XFOR
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
PremiumPress ReleasesX4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
2M ago
XFOR
X4 Pharmaceuticals announces $125M capital infusion
PremiumThe Fly
X4 Pharmaceuticals announces $125M capital infusion
2M ago
HTGC
XFOR
X4 Pharmaceuticals Advances with Strategic Financial Moves
PremiumCompany Announcements
X4 Pharmaceuticals Advances with Strategic Financial Moves
2M ago
8K
XFOR
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
PremiumPress Releases
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
2M ago
XFOR
X4 Pharmaceuticals reports Q1 EPS (26c), consensus (16c)
PremiumThe Fly
X4 Pharmaceuticals reports Q1 EPS (26c), consensus (16c)
2M ago
XFOR
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
PremiumPress Releases
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
2M ago
XFOR
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
PremiumPress Releases
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
2M ago
XFOR
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
2M ago
ALT
APLS
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2M ago
XFOR
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
ALT
AQST
X4 Pharmaceuticals price target raised to $5 from $3 at H.C. Wainwright
PremiumThe Fly
X4 Pharmaceuticals price target raised to $5 from $3 at H.C. Wainwright
2M ago
XFOR
X4 Pharmaceuticals’ Xolremdi approved for WHIM syndrome, says Cantor Fitzgerald
PremiumThe Fly
X4 Pharmaceuticals’ Xolremdi approved for WHIM syndrome, says Cantor Fitzgerald
2M ago
XFOR
Unusually active option classes on open April 29th
PremiumThe Fly
Unusually active option classes on open April 29th
2M ago
ON
BEKE
X4 Pharmaceuticals: XOLREMDI FDA Approval and Launch Update
PremiumCompany Announcements
X4 Pharmaceuticals: XOLREMDI FDA Approval and Launch Update
2M ago
8K
XFOR
X4 Pharmaceuticals Launches XOLREMDI with FDA Approval
PremiumCompany AnnouncementsX4 Pharmaceuticals Launches XOLREMDI with FDA Approval
2M ago
8K
XFOR
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
PremiumPress Releases
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
2M ago
XFOR
X4 Pharmaceuticals announces FDA approval of XOLREMDI capsules
PremiumThe Fly
X4 Pharmaceuticals announces FDA approval of XOLREMDI capsules
2M ago
XFOR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >